Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.
Recent Blog Post
April, 2024
New Study Reveals Epigenetic Markers for Type 2 Diabetes Complications in Identical Twins
23rd April 2024 – by Aaruthy Suthahar A recent collaborative effort among seven international twin cohorts, including TwinsUK, has yielded...
March, 2024
Celebrating International Women's Day: Stories from Twins and TwinsUK Staff
25th March 2024 – by Aaruthy Suthahar International Women’s Day (IWD) on March 8th is a day to celebrate the...
March, 2024
TwinsUK part of team awarded £20 million to study bowel cancer
7th March 2024 – by TwinsUK and King’s College London TwinsUK will receive part of £20m in funding by Cancer...